Known targets — ChEMBL curated mechanism
SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9A
The experimentally established mechanism targets of Mexiletine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN4A known ✓ | P35499 | 10/20 | 0.92 |
| ▸ | SCN5A known ✓ | Q14524 | 3/20 | 0.92 |
| ▸ | SCN1A known ✓ | P35498 | 2/20 | 0.92 |
| ▸ | SCN9A known ✓ | Q15858 | 2/20 | 0.92 |
| ▸ | SCN8A known ✓ | Q9UQD0 | 2/20 | 0.92 |
| ▸ | SCN7A known ✓ | Q01118 | 1/20 | 0.92 |
| ▸ | SCN2A known ✓ | Q99250 | 1/20 | 0.92 |
| ▸ | SCN3A known ✓ | Q9NY46 | 1/20 | 0.92 |
| ▸ | SCN11A known ✓ | Q9UI33 | 1/20 | 0.92 |
| ▸ | SCN10A known ✓ | Q9Y5Y9 | 1/20 | 0.92 |
| ▸ | LMNA | P02545 | 3/20 | 0.92 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.92 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.92 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.92 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.92 |
| ▸ | TSHR | P16473 | 2/20 | 0.92 |
| ▸ | MAOA | P21397 | 2/20 | 0.92 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.92 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.92 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.92 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| (R)-Mexiletine SCHEMBL16082 | 0.96 | SCN4A (1.00) | SCN4ASCN5ALMNACYP2D6SCN1A | |
| Mexiletine SCHEMBL8858385 | 0.96 | SCN4A (1.00) | SCN4ASCN5ALMNACYP2D6SCN1A | |
| (S)-Mexiletine SCHEMBL13046569 | 0.96 | SCN4A (1.00) | SCN4ASCN5ALMNACYP2D6SCN1A | |
| Mexiletine SCHEMBL16081 | 0.96 | SCN4A (1.00) | SCN4ASCN5ALMNACYP2D6SCN1A | |
| (S)-Mexiletine SCHEMBL3645798 | 0.94 | SCN5A (1.00) | SCN4ASCN5ALMNACYP2D6SCN1A | |
| Mexiletine SCHEMBL6665250 | 0.94 | SCN5A (1.00) | SCN4ASCN5ALMNACYP2D6SCN1A | |
| (R)-Mexiletine SCHEMBL29366590 | 0.94 | SCN5A (1.00) | SCN4ASCN5ALMNACYP2D6SCN1A | |
| Mexiletine SCHEMBL6521444 | 0.94 | SCN5A (1.00) | SCN4ASCN5ALMNACYP2D6SCN1A | |
| Mexiletine SCHEMBL42226 | 0.94 | SCN5A (1.00) | SCN4ASCN5ALMNACYP2D6SCN1A | |
| Mexiletine SCHEMBL8819167 | 0.86 | SCN4A (0.80) | SCN4ASCN5ALMNACYP2D6SCN1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 96 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220257665-A1 | APPLICATION OF ANTIARRHYTHMIC AGENTS TO STEM CELL DERIVED CARDIOMYOCYTES AND USES THEREOF | NOVO NORDISK A/S (DK) | 2022-08-18 | — | — | US | disclosed |
| CN-112972444-B | Application of mexiletine in preparation of product for treating and/or preventing facial and neck skin wrinkles | 中国医学科学院整形外科医院 | 2022-07-26 | — | — | CN | disclosed |
| WO-2022149605-A1 | PROPHYLACTIC OR THERAPEUTIC AGENT FOR SEVERE PULMONARY HYPERTENSION, REFRACTORY PULMONARY HYPERTENSION, OR DRUG-INDUCED PULMONARY HYPERTENSION | 国立研究開発法人国立循環器病研究センター | 2022-07-14 | — | — | WO | disclosed |
| EP-3979997-A1 | APPLICATION OF ANTIARRHYTHMIC AGENTS TO STEM CELL DERIVED CARDIOMYOCYTES AND USES THEREOF | Novo Nordisk A/S (DK) | 2022-04-13 | — | — | EP | disclosed |
| CN-113924360-A | Application of antiarrhythmic drug to stem cell-derived myocardial cells and application thereof | 诺和诺德股份有限公司 | 2022-01-11 | — | — | CN | disclosed |
| CN-112972444-A | Application of mexiletine in preparation of product for treating and/or preventing facial and neck skin wrinkles | 中国医学科学院整形外科医院 | 2021-06-18 | — | — | CN | disclosed |
| EP-3443955-B1 | PHARMACEUTICAL COMPOSITIONS FOR IMPROVING MEMORY PERFORMANCE | PHARNEXT (FR) | 2021-06-16 | — | — | EP | disclosed |
| US-20210069135-A1 | THERAPEUTIC APPROACHES FOR TREATING EPILEPSY AND RELATED DISORDERS THROUGH REDUCTION OF EPILEPTOGENESIS | PHARNEXT (FR) | 2021-03-11 | — | — | US | disclosed |
| EP-3482753-B1 | COMPOSITIONS AND THEIR USES FOR THE TREATMENT OF DIABETES AND RELATED CONDITIONS BY CONTROLLING BLOOD GLUCOSE LEVEL | PHARNEXT (FR) | 2021-01-27 | — | — | EP | disclosed |
| WO-2020245409-A1 | APPLICATION OF ANTIARRHYTHMIC AGENTS TO STEM CELL DERIVED CARDIOMYOCYTES AND USES THEREOF | NOVO NORDISK A/S (DK) | 2020-12-10 | — | — | WO | disclosed |
| US-20130090307-A1 | BACLOFEN AND ACAMPROSATE BASED THERAPY OF NEUROLOGICAL DISORDERS | PHARNEXT (FR) | 2013-04-11 | — | — | US | disclosed |
| US-20130085122-A1 | BACLOFEN AND ACAMPROSATE BASED THERAPY OF NEUROLOGICAL DISORDERS | PHARNEXT (FR) | 2013-04-04 | — | — | US | disclosed |
| EP-2560631-A2 | BACLOFEN AND ACAMPROSATE BASED THERAPY OF NEUROGICAL DISORDERS | Pharnext (FR) | 2013-02-27 | — | — | EP | disclosed |
| WO-2012117076-A2 | BACLOFEN AND ACAMPROSATE BASED THERAPY OF NEUROGICAL DISORDERS | PHARNEXT (FR) | 2012-09-07 | — | — | WO | disclosed |
| US-7927613-B2 | Pharmaceutical co-crystal compositions | UNIVERSITY OF SOUTH FLORIDA (US) | 2011-04-19 | — | — | US | disclosed |
| US-7790905-B2 | Pharmaceutical propylene glycol solvate compositions | MCNEIL-PPC, INC. (US) | 2010-09-07 | — | — | US | disclosed |
| EP-2021502-A1 | NOVEL GENES AND MARKERS IN TYPE 2 DIABETES AND OBESITY | Oy Jurilab Ltd (FI) | 2009-02-11 | — | — | EP | disclosed |
| WO-2007128884-A1 | NOVEL GENES AND MARKERS IN TYPE 2 DIABETES AND OBESITY | OY JURILAB LTD (FI) | 2007-11-15 | — | — | WO | disclosed |
| EP-1239280-A2 | ElogDoct:A tool for lipophilicity determination in drug discovery basic and neutral compounds | Pfizer Products Inc. (US) | 2002-09-11 | — | — | EP | disclosed |
| US-4731376-A | ANTIARRHYTHMIA AGENTS | ALKALOIDA VEGYESZETI GYAR (HU) | 1988-03-15 | — | — | US | disclosed |